-
2025-520809-12-00
10
2025-10-16
Diabetic Macular Edema
-
2025-521115-40-00
4
2025-09-30
Advanced or Metastatic Non-small Cell Lung Cancer
-
2024-519746-70-01
4
2025-09-15
Sickle Cell Disease
-
2024-518998-33-00
5
2025-07-23
Ulcerative Colitis
-
2024-520062-54-00
4
2025-07-23
Chronic Hepatitis D Virus (HDV) Infection
-
2025-520506-35-00
4
2025-06-30
Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
-
2024-516767-92-01
1
2025-06-17
Health Participants
-
2024-512925-95-00
5
2025-05-16
Advanced/Metastatic Breast Cancer
-
2024-515740-23-00
5
2025-03-25
Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
-
2024-515022-88-00
5
2025-03-03
Dry Age-Related Macular Degeneration (AMD) with geographic atrophy (GA
-
2023-503337-21-00
4
2025-02-28
Prophylaxis of Renal Allograft Rejection
-
2024-513015-27-00
5
2025-01-09
Moderately to Severely Active Ulcerative Colitis (UC)
-
2023-504594-20-00
1
2025-01-06
Healthy volunteers
-
2023-504359-29-01
5
2024-12-11
Multiple sclerosis
-
2024-511863-27-01
10
2024-12-06
Adult patients with ulcerative colitis diagnosed for at least 3 months
-
2024-510944-30-00
10
2024-11-22
Diabetic Macular Edema
-
2024-512147-23-00
10
2024-11-21
Chronic Lymphocytic Leukemia
-
2024-511882-13-01
5
2024-11-19
Cardiac failure
-
2023-508636-61-00
5
2024-10-24
Crohn’s Disease
-
2023-503714-77-00
4
2024-10-01
Advanced Non-Small Cell Lung Cancer
-
2022-502605-15-00
4
2024-09-16
Participants with transthyretin amyloid cardiomyopathy (ATTR CM)
-
2023-508219-21-00
5
2024-09-12
BTC - Biliary Tract Cancer
-
2023-504331-41-00
5
2024-08-02
Respiratory tract diseases - Wheezing, Asthma
-
2024-513718-37-00
4
2024-08-01
IGHV unmutated patients with high-risk stage A CLL features.